Incyte announced that the Company’s Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company’s Board of Directors, effective immediately.
Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a member of the Board through the end of the year to ensure a smooth transition. In addition, Lead Independent Director Julian Baker has been elected Chairman of the Board of Directors.
Mr. Meury is a proven enterprise leader with expertise in organizational strategy, pipeline and commercial execution and capital allocation. He most recently served as CEO of Anthos Therapeutics, where he successfully scaled the company for its next stage of growth. Prior to that, he was CEO of Karuna Therapeutics, leading its transition into a fully integrated R&D and commercial organization. Before Karuna, Mr. Meury spent more than two decades at Allergan, serving as Chief Commercial Officer, managing a global business with fifty products, $16 billion in revenue and approximately 8,000 employees across a range of therapeutic areas.
“I am honored to join Incyte at this pivotal moment and thank Hervé for his support during this transition,” said Mr. Meury. “Incyte’s track record for discovering innovative treatments for complex problems in human health is outstanding. My priority is to build upon our exceptional R&D and commercial capabilities to accelerate new product flow, drive sustainable growth and create value for all stakeholders. I look forward to working with the Incyte team to continue to grow the company for enduring success.”
“Bill is a decisive and collaborative leader who possesses the strategic planning and executional skills necessary to accelerate Incyte’s growth and maximize the tremendous opportunities we have in oncology and immunology,” said Mr. Baker. “During our thoughtful succession process, Bill’s leadership experience stood out, including his ability to effectively translate scientific breakthroughs into business results. Bill is a great listener, a tireless learner and a direct and open communicator. I believe that he embraces Incyte’s values of hard work, commitment to excellence in science and business and dedication to bringing novel, innovative and life changing medicines to patients in need. In my new role as Chairman, I look forward to working closely with Bill to create long-term value for our shareholders.”
Also Read: Illumina to Acquire SomaLogic, Boosting Proteomics Push
“On behalf of the entire Board of Directors, I want to thank Hervé for his unwavering service as Chairman and CEO of Incyte,” continued Baker. “It was at Hervé’s request last Fall that the Board of Directors engaged in a thorough succession planning process that led us to today’s transition. Hervé’s leadership and vision have been invaluable over the past decade, growing Incyte into a leading, diversified company. Hervé joined Incyte in 2014 when it was a single product, U.S.-only company. During Hervé’s tenure, Incyte launched six novel medicines plus two new indications for Jakafi, expanded commercial operations into Europe, Japan and Canada and grew revenues from $355 million dollars in 2013 to $4.2 billion today. Hervé fostered a culture of innovation and collaboration that will carry on at Incyte. I would like to thank him for his hard work and dedication to the Company, which I expect will continue through the coming years, and wish him the best in his retirement.”
“It has been a privilege to lead Incyte over the past eleven years,” said Mr. Hoppenot. “Guided by our mission to Solve On. and relying on great science, together we have achieved remarkable success in our effort to address unmet medical needs. I am proud to retire at a time when Incyte has the strongest management team, internal R&D pipeline and commercial portfolio ever. With Bill’s leadership, I am confident that the Company will continue its legacy of delivering transformative solutions to patients for many years to come.”
Source: Businesswire